757994-54-0

Upstream product

• 123-75-1 pyrrolidine 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 

Downstream Products

• 757994-56-2 N-(benzyloxycarbonyl)-3-(3-methylbuten-2-yl)-4-oxo-L-proline methyl ester 
• 394735-50-3 C₁₈H₂₁NO₅ 
• 757994-62-0 (2S,3R,4S)-4-Hydroxy-3-(3-methyl-but-2-enyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 394735-53-6 (2S,3R,4R)-4-Hydroxy-3-(2-methyl-allyl)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 757994-70-0 N-benzyloxycarbonyl-3-(2-methylallyl)-4-oxo-L-proline methyl ester 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Carboxy mediated stereoselective reduction of ketones with sodium triacetoxyborohydride: Synthesis of novel 3,4-fused tetrahydropyran and tetrahydrofuran prolines

In the presence of a carboxyl group positioned for participation, NaBH(OAc)3 will reduce the usually unreactive ketones in a stereoselective manner. This reaction was applied in a key step to prepare precursors 7 and 15 toward the title compounds 1 and 2. These results are consistent with the exchange of one of the acetoxy groups in the reducing agent with the carboxy group followed by intramolecular delivery of the hydride.